Yuichiro Ogura1, Mineo Kondo2, Kazuaki Kadonosono3, Masahiko Shimura4, Motohiro Kamei5, Akitaka Tsujikawa6. 1. Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. ogura@med.nagoya-cu.ac.jp. 2. Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan. 3. Department of Ophthalmology and Micro-technology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 4. Tokyo Medical University Hachioji Medical Center, Hachioji, Japan. 5. Aichi Medical University Hospital, Nagakute, Japan. 6. Kyoto University Graduate School of Medicine, Kyoto, Japan.
Abstract
PURPOSE: To elucidate the current clinical practice patterns of branch retinal vein occlusion (BRVO) management by retina specialists in Japan in the era of anti-vascular endothelial growth factor (VEGF) therapy. STUDY DESIGN: A voting survey using an answer pad system. METHODS: On May 28, 2017, forty-one retina specialists were surveyed on the pathology and clinical practice of BRVO management. RESULTS: Most specialists (77.5%) use fundus examination and optical coherence tomography (OCT) for diagnosis of macular edema (ME) secondary to BRVO. All assess the condition of the ellipsoid zone (EZ) and external limiting membrane (ELM) and consider this a visual prognostic factor. For ME secondary to BRVO, anti-VEGF therapy is the first choice, and most specialists (82.4%) select initial injection followed by a pro re nata (PRN) regimen. For switching to other treatment options for persistent cases, combination therapy of anti-VEGF injections and laser therapy is the most common choice (35.9%), whereas 25.6% select vitreous surgery and 15.4% select adding steroid injections. CONCLUSIONS: Our survey presents the current opinions on the diagnosis and treatment of BRVO by retina specialists in Japan, and reveals the common views about damage to the EZ/ELM as a factor of poor prognosis and anti-VEGF therapy as the first line treatment, highlighting various opinions on initiation and switching of therapy.
PURPOSE: To elucidate the current clinical practice patterns of branch retinal vein occlusion (BRVO) management by retina specialists in Japan in the era of anti-vascular endothelial growth factor (VEGF) therapy. STUDY DESIGN: A voting survey using an answer pad system. METHODS: On May 28, 2017, forty-one retina specialists were surveyed on the pathology and clinical practice of BRVO management. RESULTS: Most specialists (77.5%) use fundus examination and optical coherence tomography (OCT) for diagnosis of macular edema (ME) secondary to BRVO. All assess the condition of the ellipsoid zone (EZ) and external limiting membrane (ELM) and consider this a visual prognostic factor. For ME secondary to BRVO, anti-VEGF therapy is the first choice, and most specialists (82.4%) select initial injection followed by a pro re nata (PRN) regimen. For switching to other treatment options for persistent cases, combination therapy of anti-VEGF injections and laser therapy is the most common choice (35.9%), whereas 25.6% select vitreous surgery and 15.4% select adding steroid injections. CONCLUSIONS: Our survey presents the current opinions on the diagnosis and treatment of BRVO by retina specialists in Japan, and reveals the common views about damage to the EZ/ELM as a factor of poor prognosis and anti-VEGF therapy as the first line treatment, highlighting various opinions on initiation and switching of therapy.
Authors: Irini P Chatziralli; Adil Jaulim; Vasileios G Peponis; Panagiotis G Mitropoulos; Marilita M Moschos Journal: Semin Ophthalmol Date: 2013-10-30 Impact factor: 1.975
Authors: Peter A Campochiaro; W Lloyd Clark; David S Boyer; Jeffrey S Heier; David M Brown; Robert Vitti; Husain Kazmi; Alyson J Berliner; Kristine Erickson; Karen W Chu; Yuhwen Soo; Yenchieh Cheng; Julia A Haller Journal: Ophthalmology Date: 2014-10-12 Impact factor: 12.079
Authors: W Lloyd Clark; David S Boyer; Jeffrey S Heier; David M Brown; Julia A Haller; Robert Vitti; Husain Kazmi; Alyson J Berliner; Kristine Erickson; Karen W Chu; Yuhwen Soo; Yenchieh Cheng; Peter A Campochiaro Journal: Ophthalmology Date: 2015-10-30 Impact factor: 12.079